Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE

Autor: San-Miguel, JF, Avet-Loiseau, H, Paiva, B, Kumar, SK, Dimopoulos, MAA, Facon, T, Mateos, M-V, Touzeau, C, Jakubowiak, AJ, Usmani, SZ, Cook, G, Cavo, M, Quach, H, Ukropec, J, Ramaswami, P, Pei, H, Qi, M, Sun, S, Wang, J, Krevvata, M, DeAngelis, N, Heuck, C, Van Rampelbergh, R, Kudva, A, Kobos, R, Bahlis, NJ

In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone; D-Rd) and 58% in ALCYONE (daratumumab/bortezomib/melp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::04aa18714d279dc6478c80ac17290cab

Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/ Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

Autor: Rodriguez-Otero P, Sirvent M, González-Rodríguez AP, Lavilla E, de Coca AG, Arguiñano JM, Martí JM, Cabañas V, Motlló C, de Cabo E, Encinas C, Murillo I, Hernández-Rivas JÁ, Pérez-Persona E, Casado F, Sampol A, García R, Blanchard MJ, Anguita M, Lafuente AP, Iñigo B, López A, Ribas P, Arnao M, Maldonado R, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF

Publikováno v: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Treatment of relapsed/refractory multiple myeloma (RRMM) is highly challenging. We analyzed the efficacy and safety of pomalidomide, cyclophosphamide, and dexamethasone (PomCiDex) in a real-world RRMM population. Median progression-free and overall s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::49c58b53c0371d5391b44a73e9011383
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=9290

Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial

Autor: Weisel, K, Dimopoulos, MA, Oriol, A, Beksac, M, Dimopoulos, F, Liberati, AM, Lindsay, J, White, D, San-Miguel, JF, Moreau, P, Anderson, LD, Lorocca, A, Robak, P, Vogel, P, Jiang, RY, Grote, L, Peluso, T, Richardson, PG

Publikováno v: Clinical Lymphoma Myeloma & Leukemia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::ed5362369b6bfb3c49a7c52565bc9299
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1879

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Autor: Perez, C, Botta, C, Zabaleta, A, Puig, N, Cedena, MT, Goicoechea, I, Alameda, D, San Jose-Eneriz, E, Merino, J, Rodriguez-Otero, P, Maia, C, Alignani, D, Maiso, P, Manrique, I, Lara-Astiaso, D, Vilas-Zornoza, A, Sarvide, S, Riillo, C, Rossi, M, Rosinol, L, Oriol, A, Blanchard, MJ, Rios, R, Sureda, A, Martin, J, Martinez, R, Bargay, J, De la Rubia, J, Hernandez, MT, Martinez-Lopez, J, Orfao, A, Agirre, X, Prosper, F, Mateos, MV, Lahuerta, JJ, Blade, J, San-Miguel, JF, Paiva, B, Grp Espanol Mieloma, Programa Estudio Terapeutica Hemop

Publikováno v: Blood
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Granulocytic myeloid-derived suppressor cells (G-MDSCs) promote tumor growth and immunosuppression in multiple myeloma (MM). However, their phenotype is not well established for accurate monitoring or clinical translation. We aimed to provide the phe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::377ae14b5f4eb5e4c265343502ca5dd4
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12708

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

Autor: García-Sanz R, Corchete LA, Alcoceba M, Chillon MC, Jiménez C, Prieto I, García-Álvarez M, Puig N, Rapado I, Barrio S, Oriol A, Blanchard MJ, de la Rubia J, Martínez R, Lahuerta JJ, González Díaz M, Mateos MV, San Miguel JF, Martínez-López J, Sarasquete ME, GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en

Publikováno v: HEMATOL ONCOL
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
HEMATOLOGICAL ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname

Bortezomib- and thalidomide-based therapies have significantly contributed to improved survival of multiple myeloma (MM) patients. However, treatment-induced peripheral neuropathy (TiPN) is a common adverse event associated with them. Risk factors fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c3df1710ebadf66fd1bf959f3fac4b91
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1382